Internship

Software Engineering Summer Analyst/Associate

Posted on 1/10/2025

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Compensation Overview

$25 - $35/hr

+ Relocation Bonus + Incentive Compensation

Company Historically Provides H1B Sponsorship

Chicago, IL, USA

The internship is hybrid, requiring 3 days in-office per week.

Category
Backend Engineering
FinTech Engineering
Frontend Engineering
Full-Stack Engineering
Mobile Engineering
Web Development
Software QA & Testing
Finance & Banking
Software Engineering
Required Skills
Python
JavaScript
SQL
Requirements
  • Pursuing a Bachelor's degree (undergraduate completion in summer of 2026) OR a Master’s (advanced degree graduation between winter of 2025 and summer of 2026)
  • Computer Science / Engineering
  • Greater than 3.5 GPA
  • Javascript, Python, SQL
  • Excellent written and verbal communication skills in a variety of settings and media
  • Strong computer skills, including advanced knowledge of Google Suite and Gmail
  • A self-starter with the ability to work independently as well as in collaboration with others in a fast-paced environment
Responsibilities
  • Apply skills and knowledge learned in the classroom to on-the-job experiences
  • Work on comprehensive, value-added project(s) that help enhance the fields of science and technology
  • Collaborate with teams/colleagues in a fast-paced environment
  • Gain professional development & build relationships with peers from across the country
Desired Qualifications
  • Optional: Knowledge of GCP
  • Strong computer skills, including advanced knowledge of Google Suite and Gmail, preferred

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, distinguishing itself through its focus on personalized medicine and extensive cancer research.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Deep 6 AI expands Tempus' data network and precision medicine capabilities.
  • $560 million debt financing supports Tempus' growth and AI-driven healthcare solutions.
  • Collaboration with Artera enhances AI cancer test access, increasing Tempus' oncology influence.

What critics are saying

  • Integration challenges with Deep 6 AI could delay Tempus' expansion plans.
  • $560 million debt financing increases financial leverage, posing risk if revenue growth lags.
  • Exclusive partnership with Artera may limit Tempus' collaboration opportunities in prostate testing.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids drug development by discovering novel targets and evaluating treatments.
  • Tempus' pan-cancer organoid platform enhances personalized therapeutic opportunities for cancer patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Life Care News
Mar 30th, 2025
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.

Tempus
Mar 12th, 2025
Tempus Announces Acquisition of Deep 6 AI | Tempus AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision

TipRanks
Mar 12th, 2025
Tempus AI (TEM) Strengthens Precision Medicine with Deep 6 AI Deal, Cathie Wood Buys the Dip

Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.

Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

INACTIVE